Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

SELL
$20.13 - $27.29 $69,186 - $93,795
-3,437 Reduced 11.93%
25,380 $598,000
Q2 2023

Jul 31, 2023

BUY
$18.33 - $27.18 $528,215 - $783,246
28,817 New
28,817 $758,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Alpha Dna Investment Management LLC Portfolio

Follow Alpha Dna Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Dna Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Dna Investment Management LLC with notifications on news.